Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 47 clinical trials
Featured trial
To Evaluate the Safety and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.  

The purpose of the study is to evaluate the pharmacokinetics and safety of parsaclisib in participants With normal hepatic function and participants with hepatic impairment.

  • 0 views
  • 10 Sep, 2024
  • 3 locations
Featured trial
Fatty Liver  

[1] More than 90% of all heavy drinkers develop fatty liver while about 25% develop the more severe alcoholic hepatitis>.[4] NAFLD affects about 30% of people in Western countries and 10% of people in Asia.

hepatitis c
cancer
  • 0 views
  • 14 Mar, 2022
  • 1 location
Featured trial
Precise Profiling of Liver Disease Patients With DPMAS Therapy, Treating Optimal Patients and Achieving Hard Endpoint (PADSTONE Study) (PADSTONE)

Acute-on-chronic liver failure (ACLF) is life-threaten syndrome in patients with chronic liver disease. In China, hepatitis B virus (HBV) is the main etiology of cirrhosis and HBV-ACLF is characterized by multiple organs failure (liver, coagulation and kidney, etc.)

  • 0 views
  • 23 Nov, 2021
  • 1 location
A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection

This study evaluates the addition of Tenofovir and Entecavir in the treatment of Hepatitis B-related hepatocellular carcinoma after curative resection in adults. Half of participants will receive Tenofovir disoproxil fumarate, while the other half will receive Entecavir.

  • 0 views
  • 16 Feb, 2024
  • 1 location
Immunogenicity of 2 Versus 3 Doses of Combined Hepatitis B Vaccines in 2-18 Months Old Children

The main objective of this study is to compare the immunogenicity of the hepatitis B component in children vaccinated with (I) two doses of Infanrix-hexa administered at 2 and 12 months of age versus (II) one dose of Infanrix-hexa and one dose of Twinrix administered respectively at 2 and 12 …

twinrix
hepatitis
vaccination
infanrix
  • 0 views
  • 16 Feb, 2024
  • 2 locations
Hyperimmune Plasma in Patients With COVID-19 Severe Infection

Passive immunotherapy through plasma infusion of convalescent subjects - convalescent plasma or "hyperimmune" plasma was one of the most widespread and effective anti-infective treatments in the pre-antibiotic era and one of the founding pillars of immunology, and has also been used during the SARS (2002-2003) and Ebola (2014-2016) viral epidemy …

acute respiratory syndrome (sars)
SARS
covid-19
antibiotics
blood transfusion
  • 0 views
  • 16 Feb, 2024
  • 6 locations
Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

The pharmacokinetics of a single dose of pexidartinib will be investigated in participants with impaired hepatic function and compared with healthy control participants with normal hepatic function.

  • 0 views
  • 16 Feb, 2024
  • 2 locations
Study to Evaluate the Pharmacokinetics (PK) of E7090 and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants

The primary purpose of the study is to evaluate the effects of mild and moderate hepatic impairment on PK of E7090 after a single dose administration.

e7090
moderate hepatic impairment
electrocardiogram
moderate hepatic insufficiency
electrocardiogram (ecg)
  • 0 views
  • 16 Feb, 2024
  • 3 locations
Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic Impairment

Study to Evaluate Pharmacokinetics and Safety of SHR0302 in Patients With Mild, Moderate Hepatic Impairment and Normal Liver Function in Phase I Clinical Study

moderate hepatic impairment
moderate hepatic insufficiency
body mass index
liver disease
hepatic impairment
  • 0 views
  • 16 Feb, 2024
  • 1 location
Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Infection

This is a phase 2 study in which subjects with chronic hepatitis B virus (HBV) infection will receive VIR-2218 alone or in combination with pegylated interferon alfa-2a and will be assessed for safety, tolerability, pharmacokinetics, and antiviral activity.

interferon
hepatitis
chronic hepatitis
antiviral drugs
  • 0 views
  • 16 Feb, 2024
  • 18 locations